Open Philanthropy recommended a grant of $915,000 to Stanford University to support preclinical research on the development of a drug to cure chronic hepatitis B virus (HBV) infections and prevent HBV-induced liver cancer, led by Professor Jeffrey Glenn. If effective, the new drug could replace existing drugs that treat, but do not cure, the disease. Approximately 250 million people globally have chronic HBV, many of whom develop fatal liver cancer.
This falls within Open Philanthropy's work on scientific research, specifically within its interest in advancing human health and wellbeing.